Effectiveness Comparison of Skin Micro-grafts vs Meshed Split Thickness Skin Grafts

Sponsor
Coordinación de Investigación en Salud, Mexico (Other)
Overall Status
Unknown status
CT.gov ID
NCT02813213
Collaborator
(none)
30
1
2
27
1.1

Study Details

Study Description

Brief Summary

This is a double-blind randomized controlled clinical trial, that compares the percentage of epithelialization of skin defects using the conventional meshed split thickness skin grafts vs skin micro grafts.

Two techniques will be applied in the same patient. The skin defect will be divided in two parts, and with a randomized method each half of this defect will be assigned to one of the two techniques.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Skin micro Grafts
  • Procedure: Standard skin graft
Phase 4

Detailed Description

Split thickness skin graft is the standard technique in skin defects reconstruction.

The etiology of this problem is diverse (burns, infections, trauma, cancer) however, many times the availability of donor areas are insufficient and morbidity and complications that may arise make prohibitive the use of this technique in many situations.

Skin micro grafts technique consists in using a very small part of skin (0.8x 0.8 mm) and keratinocyte growth-factor solution that allows a 1:50- 1:100 skin expansion. It has many advantages: it can be performed with local anesthesia and donor area is tiny.

The study consists in using the conventional and the new technique in the same patient. The skin defect will be divided in two parts, and with a randomized method each half of this defect will be assigned to one of the two different techniques. The result variable will be the "percentage of epithelialization" and will be compared in the two halves. This variable will be measured at day 14 using clinical and image software methods. The patient and the investigator that record the outcome variable will be blinded to the type of technique.

The investigators will take skin biopsies of two halves and will perform pathology studies.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Experimental intervention: skin micro grafts Comparative intervention: Meshed Split Thikness Skin GraftsExperimental intervention: skin micro grafts Comparative intervention: Meshed Split Thikness Skin Grafts
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Effectiveness Comparison Between the Use of Skin Micro-grafts vs Meshed Split Thickness Skin Grafts in Cutaneous Defects: A Randomized Controlled Clinical Trial
Study Start Date :
Jun 1, 2016
Anticipated Primary Completion Date :
Aug 1, 2018
Anticipated Study Completion Date :
Sep 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Standard skin graft

This group is comprised of patients' wound halves that will receive meshed (1:3) split thickness skin graft (0.3-0.5mm thickness). This half will be covered with a standard "tie over" dressing. The dressing will be removed at day 5, and then it will be removed every 3 days up to the 14th day.

Procedure: Standard skin graft
Standard split thickness (0.3-0.5mm) skin graft
Other Names:
  • split thickness skin graft
  • skin grafting
  • skin grafts
  • medium split thickness skin graft
  • Experimental: Skin micro graft

    This group is comprised of the patients' wound halves that will receive skin micro grafts. To obtain this grafts the investigators will use "Xpansion micro-autografting" system. They will use 0.8 x 0.8 mm skin grafts with a graft to graft distance of 4mm (1:50 expansion).This half will be covered with a special hydrogel dressing with keratinocyte growth factor (Epilife medium with calcium) 1.5ml for each 14 square centimeters of the wound. This half will be covered with a wet adhesive foam dressing and then it will be covered up with a non-adherent interface dressing (tegaderm). The dressing will be removed at day 5, and then it will be removed every 3 days up to the 14th day. Each time of dressing change only the non-adherent interface dressing will be removed, and the area will be bathed with keratinocyte growth factor solution.

    Procedure: Skin micro Grafts
    0.8 x 0.8 skin micro graft with graft to graft distance of 4 cm (1:50 expansion) bathed with keratinocyte growth factor solution ( 1.5 ml for each 14 square centimeters of wound)
    Other Names:
  • Xpansion micro auto grafting system
  • micro grafts
  • Outcome Measures

    Primary Outcome Measures

    1. Percentage of epithelialization [14th day]

      It will be measured with imaging software (comparing color density) in order to calculate the percentage of epithelialization at day 14 compared with the initial wound area

    Secondary Outcome Measures

    1. Histological study [14th day]

      Study of the histological characteristics of the skin under microscope

    2. Clinical percentage of epithelialization [14th day]

      It will be measured with the "irregular patterns" technique that uses different sizes of geometric patterns in order to calculate the area of a irregular surface. Epithelialization will be compared at day 14 compared with the initial wound area.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Non complicated wounds (no infection, no cancer)

    • Wound area: 20 x 20 cms or less

    • Located in diverse anatomical regions (except axillar, groin, genital, sole, scalp and flexion or extension areas)

    Exclusion Criteria:
    • High cardiovascular risk

    • Patients with indication of a different technique

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 "La Raza" Medical Center. IMSS Azcapotzalco Mexico City Mexico 02990

    Sponsors and Collaborators

    • Coordinación de Investigación en Salud, Mexico

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Alejandro Cruz Segura, MD, Coordinación de Investigación en Salud, Mexico
    ClinicalTrials.gov Identifier:
    NCT02813213
    Other Study ID Numbers:
    • R-2013-3501-8
    First Posted:
    Jun 24, 2016
    Last Update Posted:
    Jan 26, 2018
    Last Verified:
    Jan 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Keywords provided by Alejandro Cruz Segura, MD, Coordinación de Investigación en Salud, Mexico
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 26, 2018